Conversely, in AML subtypes clearly benefitting from the combination treatment compared to HMA alone, such as NPM1- or IDH-mutated cases [141,149,262], we would generally favor the combinations, despite the risks. This evidence concerns the gene IDH1 and acute myeloid leukemia.